Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.

Abstract

BACKGROUND Atrial fibrillation is the most common sustained cardiac arrhythmia, and engenders significant health care costs. The impact of various treatment options for atrial fibrillation on hospital costs has not been evaluated in a randomized trial. METHODS We analysed 1-year follow-up data on 392 patients randomized to low dose amiodarone (200 mg. day… (More)

Topics

Cite this paper

@article{Lumer2002AmiodaroneRP, title={Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.}, author={Gerald B Lumer and Denis Roy and Mario R Talajic and Andr{\'e} Couturier and Joyce Lambert and Nancy Frasure-Smith and Bernard Thibault and Marc Dubuc and Pierre Gagn{\'e} and Stanley Nattel}, journal={European heart journal}, year={2002}, volume={23 13}, pages={1050-6} }